

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 6609)*

- (I) CHANGE IN COMPOSITION OF  
THE NOMINATION COMMITTEE;  
(II) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR;  
AND  
(III) CHANGE IN EXECUTIVE DIRECTOR'S RESPONSIBILITY**

**CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) announces that with effect from March 27, 2025, Mr. Wang Guohui ceases to be a member of the nomination committees of the Board (the “**Nomination Committee**”) in order to enhance the corporate governance of the Company and fulfil the new gender diversity requirement of the Nomination Committee under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) which will be implemented with effect from July 1, 2025. Ms. Zhang Kun (“**Ms. Zhang**”) has concurrently been appointed as a member of the Nomination Committee. Immediately following the change, the Nomination Committee will consist of two independent non-executive Directors and one executive Director, namely Mr. Feng Xiangqian (as chairman), Mr. Guo Shaomu and Ms. Zhang Kun.

Mr. Wang Guohui will remain as the chairman of the Board, chief executive officer and an executive Director of the Company, as well as the chairman of the strategy committee of the Board and a member of the remuneration committee of the Board. Mr. Wang Guohui has confirmed that he has no disagreement with the Board and is not aware of other matters about his cessation as the member of the Nomination Committee that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

## CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Company held a meeting of the employee representative on March 27, 2025 and elected Mr. Liu Baiwei (“**Mr. Liu**”) as an employee representative supervisor (the “**Employee Representative Supervisor**”) of the second session of the supervisory committee of the Company (the “**Supervisory Committee**”). The appointment of Mr. Liu as the Employee Representative Supervisor shall take effect from March 27, 2025 and his term of office will be in line with that of the second session of the Supervisory Committee and he shall not receive any remuneration as the Employee Representative Supervisor during the term of his office. Mr. Liu was further appointed as the chairman of the Supervisory Committee. On the same day, Mr. Xue Zongyu tendered his resignation as supervisor of the Company due to his other personal commitments and ceased to perform his duties as an Employee Representative Supervisor and the Chairman of the Supervisory Committee, and has confirmed that he has no disagreement with the Board, the Supervisory Committee or the Company, and that there are no other matters in relation to his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange and there is no existing or pending litigation or claim by him against the Group. The Company would like to take this opportunity to express its gratitude to Mr. Xue Zongyu for his contributions to the Group during his term of service as a supervisor of the Company.

The biographical details of Mr. Liu are set out below:

Mr. Liu, aged 31, joined the Company in November 2024 as the director of finance and investor relations. Prior to joining the Company, he worked at the investment banking department of Sinolink Securities Co., Ltd. from August 2017 to October 2024, where his focus was primarily responsible for initial public offerings, mergers and acquisitions, and refinancing for companies in the biopharmaceutical industry. He has extensive experience in capital markets and financial management.

Mr. Liu obtained his bachelor of engineering from Donghua University in June 2015 and a master of management from the University of Sheffield in December 2016.

As at the date of this announcement, Mr. Liu confirmed that: (i) he does not related to any other directors, supervisors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) he does not hold and have not held any directorship in any other public companies whose shares were listed in Hong Kong or any overseas stock exchange in the past three years and he does have and have not held other major appointments or professional qualifications; (iii) he has or is deemed to have any interest in the shares or underlying shares of the Company or associated corporations (as defined in Part XV of the Securities and Futures Ordinance) (Chapter 571 of the Laws of Hong Kong); and (iv) no other matters are required to be brought to the attention of Shareholders or the Stock Exchange or required to be disclosed under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules. Also, save as disclosed above, Mr. Liu does not hold any other positions in the Company or other members of the Group.

## CHANGE IN EXECUTIVE DIRECTOR'S RESPONSIBILITY

The Board announces that with effect from March 27, 2025, Ms. Zhang will cease to serve as a deputy general manager of the Company due to internal work adjustments of the Company. Ms. Zhang continues to serve on the Board as an executive director and a member of the strategy committee of the Board and a member of the Nomination Committee and will remain as a member of the Group's management team.

Biographical information of Ms. Zhang is set out in the Company's annual report for the year ended December 31, 2023 which was published on April 17, 2024. Save as disclosed in this announcement, as at the date of this announcement, there has been no other change of such information. Save for the information set out above, there is no other information to be disclosed pursuant to the requirements of the provisions under Rule 13.51(2) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders in relation to the change of the executive responsibilities of Ms. Zhang.

By order of the Board

**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, March 27, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*